Literature DB >> 21454686

Identification of constitutively active interleukin 33 (IL-33) splice variant.

Jaewoo Hong1, Suyoung Bae, Hyunjhung Jhun, Siyoung Lee, Jida Choi, Taebong Kang, Areum Kwak, Kwangwon Hong, Eunsom Kim, Seunghyun Jo, Soohyun Kim.   

Abstract

IL-33/IL-1F11 is a new member of the IL-1 family ligand and provokes T helper-type immune responses. IL-33 is the ligand of ST2 and IL-1 receptor accessory protein (IL-1RAcP) that triggers nuclear factor-κ light chain enhancer of activated B cells (NF-κB) and MAPK signaling. We discovered a novel short splice variant of IL-33 that was termed spIL-33. The new spIL-33 lacks exon 3 containing a proposed caspase-1 cleavage site. We isolated spIL-33 cDNA from the Huh7 human hepatocarcinoma cell line and expressed the recombinant spIL-33 protein in Escherichia coli. The recombinant spIL-33 and pro-IL-33 were not cleaved by caspase-1, unlike IL-18 (IL-1F4). The recombinant spIL-33 was constitutively active, and spIL-33-induced inflammatory cytokine production was caspase-1-independent in HMC-1 and Raw 264.7 cells. The recombinant spIL-33 induced the phosphorylation of IL-1 receptor-associated kinase (IRAK1), NF-κB, p38 MAPK, p44/42 MAPK, and JNK in a time- and dose-dependent manner. Anti-ST2 monoclonal antibody specifically blocked the spIL-33-induced cytokine production. In this study, we identified and characterized a new IL-33 splice variant, which was a constitutively active IL-33 isoform. The existence of constitutively active spIL-33 suggests that the biological activity of IL-33 could be triggered by diverse stimulations during immune responses. Further investigation of the spIL-33 expression pattern may contribute to understanding the involvement of IL-33 in inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454686      PMCID: PMC3103380          DOI: 10.1074/jbc.M111.219089

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

Review 1.  RNA processing and human disease.

Authors:  A V Philips; T A Cooper
Journal:  Cell Mol Life Sci       Date:  2000-02       Impact factor: 9.261

2.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy.

Authors:  Waldiceu A Verri; Fabrício O Souto; Silvio M Vieira; Sergio C L Almeida; Sandra Y Fukada; Damo Xu; Jose C Alves-Filho; Thiago M Cunha; Ana T G Guerrero; Rafaela B Mattos-Guimaraes; Fabíola R Oliveira; Mauro M Teixeira; João S Silva; Iain B McInnes; Sergio H Ferreira; Paulo Louzada-Junior; Foo Y Liew; Fernando Q Cunha
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

4.  Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3.

Authors:  C Coeshott; C Ohnemus; A Pilyavskaya; S Ross; M Wieczorek; H Kroona; A H Leimer; J Cheronis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response.

Authors:  D Novick; S H Kim; G Fantuzzi; L L Reznikov; C A Dinarello; M Rubinstein
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

6.  Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages.

Authors:  Tatsukuni Ohno; Keisuke Oboki; Naoki Kajiwara; Eiichi Morii; Katsuyuki Aozasa; Richard A Flavell; Ko Okumura; Hirohisa Saito; Susumu Nakae
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

Review 7.  IL-1, IL-18, and IL-33 families of cytokines.

Authors:  William P Arend; Gaby Palmer; Cem Gabay
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells.

Authors:  Molly D Smithgall; Michael R Comeau; Bo-Rin Park Yoon; Dawn Kaufman; Richard Armitage; Dirk E Smith
Journal:  Int Immunol       Date:  2008-06-11       Impact factor: 4.823

9.  T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses.

Authors:  M J Townsend; P G Fallon; D J Matthews; H E Jolin; A N McKenzie
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

10.  The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function.

Authors:  K Hoshino; S Kashiwamura; K Kuribayashi; T Kodama; T Tsujimura; K Nakanishi; T Matsuyama; K Takeda; S Akira
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

View more
  37 in total

1.  Quantitative phosphoproteomic analysis of IL-33-mediated signaling.

Authors:  Sneha M Pinto; Raja Sekhar Nirujogi; Pamela Leal Rojas; Arun H Patil; Srikanth S Manda; Yashwanth Subbannayya; Juan Carlos Roa; Aditi Chatterjee; T S Keshava Prasad; Akhilesh Pandey
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

2.  Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity.

Authors:  Suyoung Bae; Taebong Kang; Jaewoo Hong; Siyoung Lee; Jida Choi; Hyunjhung Jhun; Areum Kwak; Kwangwon Hong; Eunsom Kim; Seunghyun Jo; Soohyun Kim
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

3.  Dynamic role of epithelium-derived cytokines in asthma.

Authors:  Kathleen R Bartemes; Hirohito Kita
Journal:  Clin Immunol       Date:  2012-03-20       Impact factor: 3.969

4.  A network map of IL-33 signaling pathway.

Authors:  Sneha M Pinto; Yashwanth Subbannayya; D A B Rex; Rajesh Raju; Oishi Chatterjee; Jayshree Advani; Aneesha Radhakrishnan; T S Keshava Prasad; Mohan R Wani; Akhilesh Pandey
Journal:  J Cell Commun Signal       Date:  2018-04-28       Impact factor: 5.782

5.  The inhibitory function of Fc-ST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity.

Authors:  Kwangwon Hong; Youngmin Lee; Siyoung Lee; Sungnoh Hong; Suyoung Bae; Jaewoo Hong; Jida Choi; Hyunjhung Jhun; Areum Kwak; Eunsom Kim; Seunghyun Jo; Taebong Kang; You Sook Cho; Yong-Gil Kim; Soohyun Kim
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 6.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

7.  IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis.

Authors:  Jakob Benedict Seidelin; Mehmet Coskun; Peter Helding Kvist; Thomas Lindebo Holm; Kristine Holgersen; Ole Haagen Nielsen
Journal:  J Gastroenterol       Date:  2014-08-12       Impact factor: 7.527

Review 8.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

9.  Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity.

Authors:  Tao Liu; Nora A Barrett; Yoshihide Kanaoka; Eri Yoshimoto; Denise Garofalo; Haley Cirka; Chunli Feng; Joshua A Boyce
Journal:  J Immunol       Date:  2017-12-27       Impact factor: 5.422

Review 10.  Insights into the initiation of type 2 immune responses.

Authors:  Chris J Oliphant; Jillian L Barlow; Andrew N J McKenzie
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.